Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-4-28
|
| pubmed:abstractText |
The pharmacokinetic parameters of amikacin and ceftazidime were assessed in four patients undergoing hemofiltration for septic shock. The parameters were assessed during hemofiltration and in the interim period. The concentration-time profiles of these two drugs in plasma, urine, and ultrafiltrate were investigated after intravenous perfusion (30 min). In all cases a 1-g dose of ceftazidime was administered; for amikacin, the dosage regimen was adjusted according to the patient's amikacin levels (250 to 750 mg). Concentrations of drug in all samples were assayed by high-performance liquid chromatography with UV detection for ceftazidime and by enzyme multiplied immunoassay for amikacin. The elimination half-life (t1/2) and the total clearance of amikacin ranged from 31.1 to 138.2 h and from 5.4 to 8.9 ml/min, respectively, during the interhemofiltration period in anuric patients. Hemofiltration substantially decreased the t1/2 (3.5 +/- 0.49 h) and increased the total clearance (89.5 +/- 11.8 ml/min). The hemofiltration clearance of amikacin represented 71% of the total clearance, and the hemofiltration process removed, on average, 60% of the dose. During hemofiltration, the elimination t1/2 of ceftazidime (2.8 +/- 0.69 h) was greatly reduced and the total clearance increased (74.2 +/- 11.2 ml/min) compared with those in the interhemofiltration period (9 to 43.7 h and 7.4 to 16.8 ml/min, respectively). About 55% of the administered dose was recovered in the filtrate, and the hemofiltration clearance of ceftazidime was 46 +/- 14.3 ml/min. A redistribution phenomenon (rebound) in the amikacin and ceftazidime concentrations in plasma (35 and 28%, respectively) was reported after hemofiltration in two patients. The MICs for 90% of the most important pathogens were exceeded by the concentrations of the two drugs in plasma during the whole treatment of these patients.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-1510435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-2111658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-2510061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-2511798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-2785286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-3197752,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-3214972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-3757406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-3969624,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-4086708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-423486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-608876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-608877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-6375562,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-6378086,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-6386696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8460915-848923
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0066-4804
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
464-73
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:8460915-Adult,
pubmed-meshheading:8460915-Aged,
pubmed-meshheading:8460915-Amikacin,
pubmed-meshheading:8460915-Body Weight,
pubmed-meshheading:8460915-Ceftazidime,
pubmed-meshheading:8460915-Critical Care,
pubmed-meshheading:8460915-Drug Administration Schedule,
pubmed-meshheading:8460915-Female,
pubmed-meshheading:8460915-Hemofiltration,
pubmed-meshheading:8460915-Humans,
pubmed-meshheading:8460915-Infusions, Intravenous,
pubmed-meshheading:8460915-Male,
pubmed-meshheading:8460915-Middle Aged,
pubmed-meshheading:8460915-Multiple Organ Failure,
pubmed-meshheading:8460915-Shock, Septic,
pubmed-meshheading:8460915-Software
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.
|
| pubmed:affiliation |
Laboratoire de Pharmacocinétique, Pharmacie Carémeau, Centre Hospitalier Universitaire, Nimes, France.
|
| pubmed:publicationType |
Journal Article
|